If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||
  CephalalgiaVolume 9 Issue 1, Pages 29 - 32 Published Online: 19 Jan 2002 © 2009 International Headache Society Published on behalf of the International Headache Society
Abstract | Full Text: PDF (Size: 27K) | Related Articles | Citation Tracking  Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks Copyright International Headache Society KEYWORDS Comparative study • migraine • naproxen • placebo ABSTRACTNaproxen was compared with placebo in a double-blind, crossover trial in classic and common migraine. The trial was terminated at a fixed date; 37 patients had entered, 5 of whom were excluded. Naproxen was given as 750 mg at the first symptom of the attack, a total of 1250 mg per 24 h was allowed. Patients were followed for six attacks or three months in each phase, whichever came first. The severity of the headache was significantly less with naproxen in the first 2 h of the attack (p=0.047), whereas there was no difference when the whole attack was considered. Significantly more patients preferred naproxen (p=0.042). Side effects occurred in five patients, causing withdrawal of one patient while on naproxen. Accepted 22 August 1988 | 
|
